ONE-P TMS First Responders (ONE-P_FR)
One-day rTMS + D-cycloserine to Treat PTSD in First Responders
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Detaljert beskrivelse
Studietype
Studietype
Registrering (Antatt)
Registrering
Fase
Fase
- Fase 2
Kontakter og plasseringer
Studiekontakt
Studiekontakt
- Navn: Amanda Ding, BSc
- Telefonnummer: (604)-822-7308
- E-post: ninet.lab@ubc.ca
Studiesteder
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6T 2A1
- Non-Invasive Neurostimulation Therapies Centre, University of British Columbia
-
Ta kontakt med:
- Amanda Ding
- Telefonnummer: (604)-822-7308
- E-post: ninet.lab@ubc.ca
-
Hovedetterforsker:
- Fidel Vila-Rodriguez
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
Tar imot friske frivillige
Beskrivelse
Inclusion Criteria:
- are outpatients between the ages of 19-60;
- are voluntary and competent to consent;
- are first responders (active, on leave or retired);
- have DSM-5 diagnosis of PTSD with a CAPS for DSM-5 (CAPS-5) score ≥ 25;
- 17-item Hamilton Depression Rating Scale score ≤ 23;
- have had no increase or initiation of any psychotropic medication in the 4 weeks prior to screening;
- if participating in psychotherapy, must have been in stable treatment for at least 1 month prior to entry into the study, with no anticipation of change in the frequency of therapeutic sessions, or the therapeutic focus over the duration of the study;
- able to adhere to the treatment schedule;
- Pass the TMS adult safety screening (TASS) questionnaire, and the MRI safety screening.
Exclusion Criteria:
- have a Severe Substance Use Disorder (except tobacco) within the last three (3) months;
- have a concomitant major unstable medical illness, cardiac pacemaker or implanted medication pump;
- have active suicidal intent;
- are pregnant;
- have a lifetime MINI diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, or current psychotic symptoms;
- have a MINI diagnosis of OCD, or mood disorder that is assessed by a study investigator to be primary and causing greater impairment than PTSD;
- have a diagnosis of any personality disorder, assessed by a study investigator to be primary and causing greater impairment than MDD;
- have failed a course of ECT in the current episode or previous episode;
- have received rTMS for any previous indication;
- have any significant neurological disorder, history of seizure disorder (except those therapeutically induced by ECT), or any significant head trauma with clear radiological evidence of cerebrovascular injury on imaging;
- have an intracranial implant (e.g., aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or any other metal object within or near the head, excluding the mouth, that cannot be safely removed;
- clinically significant laboratory abnormality, in the opinion of the one of the principal investigators or study physicians (including but not limited to abnormal blood urea nitrogen (BUN), creatinine, estimated glomerular filtration rate (eGFR));
- currently take more than lorazepam 2 mg daily (or equivalent) or any dose of an anticonvulsant due to the potential to limit rTMS efficacy;
- currently take dicumarol, gingko biloba, isoniazid, ethionamide, fluphenazine, metrizamide, tramadol, warfarin due to potential interactions with D-Cycloserine;
- planned vaccination with Bacille Calmette-Guérin, cholera or typhoid or planned imaging procedure with an injectable die, within one week following the treatment days, due to potential interactions with DCS.
- allergy to DCS
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Trippel
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Eksperimentell: active aiTBS plus DCS
|
Participants randomized to the active treatment arm will receive DCS 125 mg orally, administered as one capsule around one hour before active aiTBS treatment.
rTMS will employ the MagPro X100/R30 stimulator (MagVenture, Farum, Denmark) equipped with the B70 coil. A scalp heuristic will be used to localize the treatment site over the right DLPFC by modifying the BeamF3 method to the contralateral side. We have previously reported good congruency between the BeamF3 heuristic method and MRI-guided neuronavigation. Prior to the first treatment, each subject's resting motor threshold (RMT) will first be determined according to published methods. Patients will receive 3 minutes of iTBS every 30 minutes for a total of 15 session over two separate days three weeks apart day of treatment using the following parameters: 50 Hz triplet bursts, 5 bursts per second, 2 s on and 8 s off for 20 trains of 600 pulses, preceded by an introductory 3-train acclimatization titration, at an intensity of 80% of the RMT. The treatment protocol will be repeated 3 weeks after the initial treatment day. |
|
Placebo komparator: active aiTBS plus placebo DCS
|
rTMS will employ the MagPro X100/R30 stimulator (MagVenture, Farum, Denmark) equipped with the B70 coil. A scalp heuristic will be used to localize the treatment site over the right DLPFC by modifying the BeamF3 method to the contralateral side. We have previously reported good congruency between the BeamF3 heuristic method and MRI-guided neuronavigation. Prior to the first treatment, each subject's resting motor threshold (RMT) will first be determined according to published methods. Patients will receive 3 minutes of iTBS every 30 minutes for a total of 15 session over two separate days three weeks apart day of treatment using the following parameters: 50 Hz triplet bursts, 5 bursts per second, 2 s on and 8 s off for 20 trains of 600 pulses, preceded by an introductory 3-train acclimatization titration, at an intensity of 80% of the RMT. The treatment protocol will be repeated 3 weeks after the initial treatment day.
Participants randomized to the placebo arm will receive one matched placebo capsule administered orally at the same time point and according to the same procedures as the active investigational product.
|
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Feasibility of one-day iTBS+DCS: Enrolment
Tidsramme: 2 years
|
Enrollment rate: participants enrolled ÷ enrolment target by the end of 1.5 years will be ≥ 70% of the enrollment targe
|
2 years
|
|
Feasibility: Adherence
Tidsramme: 2 years
|
Proportion of randomized participants receiving ≥80% of scheduled iTBS sessions, defined as ≥24 session
|
2 years
|
|
Feasibility: dropout rates
Tidsramme: 2 years
|
Percentage of dropout rates attributable to the intervention will be ≤ 10%
|
2 years
|
Andre resultatmål
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Treatment group differences in change from baseline to 3-weeks post-treatment on the Clinician-Administered Posttraumatic Stress Disorder Scale for DSM 5 (CAPS-5) Total Severity Score
Tidsramme: 3 weeks
|
Exploratory efficacy outcome: change in Clinician-Administered PTSD Scale for DSM 5 (CAPS-5).
Total Severity Score (20 item sum, range 0-80, higher score=greater severity) in change from baseline to 3-weeks after the intervention
|
3 weeks
|
|
Treatment group differences in change from baseline to 6-weeks post-treatment on the Clinician-Administered Posttraumatic Stress Disorder Scale for DSM 5 (CAPS-5) Total Severity Score
Tidsramme: 6 weeks
|
Exploratory efficacy outcome: change in Clinician-Administered PTSD Scale for DSM 5 (CAPS-5).
Total Severity Score (20-item sum, range 0-80, higher score=greater severity) in change from baseline to 6-weeks after the intervention.
Weathers, FW, Blake, DD, Schnurr, PP, Kaloupek, DG, Marx, BP, & Keane, TM.
The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5).
www.ptsd.va.gov:
National Center for PTSD, 2013
|
6 weeks
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Etterforskere
Etterforskere
- Hovedetterforsker: Fidel Vila-Rodriguez, M.D., PhD, FRCPC, DFAPA, University of British Columbia
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Studiestart
Primær fullføring (Antatt)
Primær fullføring
Studiet fullført (Antatt)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Traumer og stressorerelaterte lidelser
- Psykiske lidelser
- Stresslidelser, traumatiske
- Stresslidelser, posttraumatisk
- Kampforstyrrelser
- Aminosyrer, peptider og proteiner
- Heterocykliske forbindelser, 1-ring
- Heterocykliske forbindelser
- Azoler
- Aminosyrer
- Oksazolidinoner
- Oksazoler
- Isoxazoles
- Serin
- Aminosyrer, nøytrale
- Cycloserin
Andre studie-ID-numre
Andre studie-ID-numre
- H25-03191
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .